Early and Late Side Effects and Patient Management in I-131 Treatment
Journal Title: Nuclear Medicine Seminars - Year 2021, Vol 7, Issue 1
Abstract
I-131 is the first most experienced theranostic radionuclide that has been used since the early 1940s for the treatment of hyperthyroidism, metastases or ablation of residual thyroid tissue in well-differentiated thyroid cancers. Although generally safe and very well tolerated, radioiodine therapy has some potential side effects classified as early and late complications. Early side effects include nausea, rarely vomiting, oral mucositis, sialadenitis, taste disturbance, gastrointestinal, gonadal and hematopoietic system dysfunction and radiation thyroiditis in the cases with large residual tissue. Late complications include secondary cancers, pulmonary fibrosis, and permanent bone marrow suppression. Early complications are generally due to the radioiodine activity and have transient nature, late complications are due to the cumulative radiation dose and are rare. The aim of this article is to review the potential side effects and complications of I-131 therapy and their clinical management.
Authors and Affiliations
Mehmet Reyhan
Keywords
Related Articles
- EP ID EP693443
- DOI 10.4274/nts.galenos.2021.0009
- Views 77
- Downloads 0
Renal Toxicity After Radionuclide Therapy
With the introduction of radionuclide therapies, the probability of toxicity has increased in critical organs such as kidney and bone marrow. Although these toxicity rates are relatively low in targeted therapies such as...
F-18 FDG PET/CT Practice Guideline in Oncology
Positron emission tomography (PET) is a tomographic imaging method that shows three-dimensional distribution of radiopharmaceuticals which are labelled with positron emitter radionuclides. Today most widely used PET radi...
Guideline for the Treatment of Liver Cancer with Y-90 Radiomicrosphere
Yttrium-90 microsphere therapy, which has become more common in recent years, offers an effective and safe radionuclide treatment option in the treatment of primary and metastatic liver tumors. The success of the treatme...
Practical Guidance on Peptide Receptor Radionuclide Therapy
Peptide receptor radionuclide therapy (PRRT) have been successfully used for the past 20 years to target metastatic or inoperable neuroendocrine tumors expressing the somatostatin receptors. Both prospective and retrospe...
Options and Auxiliary Surgical Techniques in Residual or Recurrent Nodal Disease in Differentiated Thyroid Cancers
Despite their very good prognosis, residual or recurrent nodal disease can be seen in approximately 30% of patients in differentiated thyroid cancers (DTC). Nodal disease is most common in the neck and it can be treated...